Skip to main content
Top
Published in: Rheumatology International 10/2013

01-10-2013 | Short Communication

Short-term efficacy of topical capsaicin therapy in severely affected fibromyalgia patients

Authors: Benigno Casanueva, Baltasar Rodero, Covadonga Quintial, Javier Llorca, Miguel A. González-Gay

Published in: Rheumatology International | Issue 10/2013

Login to get access

Abstract

The purpose of this study was to evaluate the short-term efficacy of topical capsaicin treatment in patients severely affected by fibromyalgia. One hundred and thirty fibromyalgia patients were randomly divided into two groups. The control group, 56 women and 4 men who continued their medical treatment, and the capsaicin group, 70 women who apart from continuing their medical treatment, also underwent topical capsaicin 0.075 % 3 times daily for 6 weeks. At the beginning of the program, there were no significant differences between the two groups in any of the analyzed parameters. At the end of the treatment, there were significant improvements in the capsaicin group in the myalgic score (5.21 vs 3.8, p = 0.02) and global subjective improvement (22.8 vs 5 %, p = 0.001). Six weeks after the end of the treatment, the experimental group showed significant differences in Visual Analogue Scale of depression (5.63 vs 7.35, p = 0.02), Fibromyalgia Impact Questionnaire (67.89 vs 77.7, p = 0.02), role limitations due to emotional problems (36.17 vs 17.2, p = 0.05), Fatigue Severity Scale (6.2 vs 6.6, p = 0.04), myalgic score (3.94 vs 2.66, p = 0.02) and pressure pain threshold (79.25 vs 56.71, p = 0.004). In conclusion, patients severely affected by fibromyalgia can obtain short-term improvements following topical capsaicin 0.075 % treatment three times daily for 6 weeks.
Literature
1.
go back to reference Wolfe F, Smythe HA, Yunus MB et al (1990) The American College of Rheumatology 1990 criteria for the classification of FM: report of the Multicenter Criteria Committee. Arthritis Rheum 33(2):160–172PubMedCrossRef Wolfe F, Smythe HA, Yunus MB et al (1990) The American College of Rheumatology 1990 criteria for the classification of FM: report of the Multicenter Criteria Committee. Arthritis Rheum 33(2):160–172PubMedCrossRef
2.
go back to reference Staud R (2002) Evidence of involvement of central neural mechanisms in generating fibromyalgia pain (review). Curr Rheumatol Rep 4(4):299–305PubMedCrossRef Staud R (2002) Evidence of involvement of central neural mechanisms in generating fibromyalgia pain (review). Curr Rheumatol Rep 4(4):299–305PubMedCrossRef
3.
go back to reference Herpfer I, Lieb K (2003) Substance P and substance P receptor antagonists in the pathogenesis and treatment of affective disorders. World J Biol Psychiatry 4(2):56–63PubMedCrossRef Herpfer I, Lieb K (2003) Substance P and substance P receptor antagonists in the pathogenesis and treatment of affective disorders. World J Biol Psychiatry 4(2):56–63PubMedCrossRef
4.
go back to reference Russell IJ, Orr MD, Littman B et al (1994) Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 37(11):1593–1601PubMedCrossRef Russell IJ, Orr MD, Littman B et al (1994) Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 37(11):1593–1601PubMedCrossRef
5.
go back to reference Nolano M, Simone DA, Wendelschafer-Crabb G et al (1999) Topical capsaicin in humans: parallel loss of epidermal nerve fibres and pain sensation. Pain 81(1–2):135–145PubMedCrossRef Nolano M, Simone DA, Wendelschafer-Crabb G et al (1999) Topical capsaicin in humans: parallel loss of epidermal nerve fibres and pain sensation. Pain 81(1–2):135–145PubMedCrossRef
6.
go back to reference Morgenlander JC, Hurwitz BJ, Massey EW (1990) Capsaicin for the treatment of pain in Guillain-Barré syndrome. Ann Neurol 28(2):199PubMedCrossRef Morgenlander JC, Hurwitz BJ, Massey EW (1990) Capsaicin for the treatment of pain in Guillain-Barré syndrome. Ann Neurol 28(2):199PubMedCrossRef
7.
go back to reference Mason L, Moore RA, Derry S et al (2004) Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 328(7446):991PubMedCrossRef Mason L, Moore RA, Derry S et al (2004) Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 328(7446):991PubMedCrossRef
8.
go back to reference Vargas A, Vargas A, Hernandez-Paz R et al (2006) Sphygmomanometry-evoked allodynia-a simple bedside test indicative of fibromyalgia: a multicentre developmental study. J Clin Rheumatol 12(6):272–274PubMedCrossRef Vargas A, Vargas A, Hernandez-Paz R et al (2006) Sphygmomanometry-evoked allodynia-a simple bedside test indicative of fibromyalgia: a multicentre developmental study. J Clin Rheumatol 12(6):272–274PubMedCrossRef
9.
go back to reference Lázaro C, Bosch F, Torrubia R et al (1994) The development of a Spanish questionnaire for assessing pain: preliminary data concerning reliability and validity. Eur J Psychol Assess 10(2):145–151 Lázaro C, Bosch F, Torrubia R et al (1994) The development of a Spanish questionnaire for assessing pain: preliminary data concerning reliability and validity. Eur J Psychol Assess 10(2):145–151
10.
go back to reference Tan G, Jensen MP, Thornby JI et al (2004) Validation of the brief pain inventory for chronic nonmalignant pain. J Pain 5(2):133–137PubMedCrossRef Tan G, Jensen MP, Thornby JI et al (2004) Validation of the brief pain inventory for chronic nonmalignant pain. J Pain 5(2):133–137PubMedCrossRef
11.
go back to reference Krupp LB, LaRocca NG, Muir-Nash J et al (1989) The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1124PubMedCrossRef Krupp LB, LaRocca NG, Muir-Nash J et al (1989) The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121–1124PubMedCrossRef
12.
go back to reference Royuela Rico A, Macías Fernández JA (1997) Propiedades clinimétricas de la versión castellana del cuestionario de Pittsburgh. Vigilia-Sueño 9(2):81–94 Royuela Rico A, Macías Fernández JA (1997) Propiedades clinimétricas de la versión castellana del cuestionario de Pittsburgh. Vigilia-Sueño 9(2):81–94
13.
go back to reference Beck AT, Brown G, Epstein N et al (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consul Clin Psychol 56:893–897CrossRef Beck AT, Brown G, Epstein N et al (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consul Clin Psychol 56:893–897CrossRef
14.
go back to reference Beck AT, Ward CH, Mendelson M et al (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571PubMedCrossRef Beck AT, Ward CH, Mendelson M et al (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571PubMedCrossRef
15.
go back to reference García Campayo J, Rodero B, Alda M et al (2008) Validation of the Spanish version of the Pain Catastrophizing Scale in fibromyalgia. Med Clín 131(13):487–492CrossRef García Campayo J, Rodero B, Alda M et al (2008) Validation of the Spanish version of the Pain Catastrophizing Scale in fibromyalgia. Med Clín 131(13):487–492CrossRef
16.
go back to reference Rivera J, Gonzalez T (2004) The Fibromyalgia impact questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol 22(5):554–560PubMed Rivera J, Gonzalez T (2004) The Fibromyalgia impact questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol 22(5):554–560PubMed
17.
go back to reference Bruce B, Fries JF (2003) The Stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcomes 1(1):20PubMedCrossRef Bruce B, Fries JF (2003) The Stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcomes 1(1):20PubMedCrossRef
18.
go back to reference Harwood RH, Rogers A, Dickinson E et al (1994) Measuring handicap: the London handicap scale a new outcome measure for chronic disease. Qual Health Care 3(1):11–16PubMedCrossRef Harwood RH, Rogers A, Dickinson E et al (1994) Measuring handicap: the London handicap scale a new outcome measure for chronic disease. Qual Health Care 3(1):11–16PubMedCrossRef
19.
go back to reference Staud R (2010) Is it all central sensitization? Role of peripheral tissue nociception in chronic musculoskeletal pain. Cur Rheumatol Rep 12(6):448–454CrossRef Staud R (2010) Is it all central sensitization? Role of peripheral tissue nociception in chronic musculoskeletal pain. Cur Rheumatol Rep 12(6):448–454CrossRef
20.
go back to reference Hong CZ, Hsueh TC (1996) Difference in pain relief after trigger point injections in myofascial pain patients with and without fibromyalgia. Arch Phys Med Rehabil 77(11):1161–1166PubMedCrossRef Hong CZ, Hsueh TC (1996) Difference in pain relief after trigger point injections in myofascial pain patients with and without fibromyalgia. Arch Phys Med Rehabil 77(11):1161–1166PubMedCrossRef
21.
go back to reference Morris V, Cruwys S, Kidd B (1998) Increased capsaicin-induced secondary hyperalgesia as a marker of abnormal sensory activity in patients with fibromyalgia. Neurosci Lett 250(3):205–207PubMedCrossRef Morris V, Cruwys S, Kidd B (1998) Increased capsaicin-induced secondary hyperalgesia as a marker of abnormal sensory activity in patients with fibromyalgia. Neurosci Lett 250(3):205–207PubMedCrossRef
22.
go back to reference McCarty DJ, Csuka M, McCarthy G et al (1994) Treatment of pain due to fibromyalgia with topical capsaicin: a pilot study. Semin Arthritis Rheum 23(Suppl 3):41–47CrossRef McCarty DJ, Csuka M, McCarthy G et al (1994) Treatment of pain due to fibromyalgia with topical capsaicin: a pilot study. Semin Arthritis Rheum 23(Suppl 3):41–47CrossRef
23.
go back to reference Acasuso Diaz M, Collantes Estevez E, Jordi Reus S (1998) Capsaicina versus ketoprofen en tratamiento tópico de la fibromialgia primaria. XXIV Congreso Nacional de la Sociedad Española de Reumatología, Cádiz, Junio Acasuso Diaz M, Collantes Estevez E, Jordi Reus S (1998) Capsaicina versus ketoprofen en tratamiento tópico de la fibromialgia primaria. XXIV Congreso Nacional de la Sociedad Española de Reumatología, Cádiz, Junio
24.
go back to reference Ebner K, Muigg P, Singewald G et al (2008) Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry. Ann NY Acad Sci 1144:61–73PubMedCrossRef Ebner K, Muigg P, Singewald G et al (2008) Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry. Ann NY Acad Sci 1144:61–73PubMedCrossRef
25.
go back to reference Wallace DJ, Linker-Israeli M, Hallegua D et al (2001) Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxford) 40(7):743–749CrossRef Wallace DJ, Linker-Israeli M, Hallegua D et al (2001) Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxford) 40(7):743–749CrossRef
Metadata
Title
Short-term efficacy of topical capsaicin therapy in severely affected fibromyalgia patients
Authors
Benigno Casanueva
Baltasar Rodero
Covadonga Quintial
Javier Llorca
Miguel A. González-Gay
Publication date
01-10-2013
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 10/2013
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-012-2490-5

Other articles of this Issue 10/2013

Rheumatology International 10/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine